➣ Special Issue: Case Report
➣ Diab Res Open Access. 2020 Apr 14;2(S1):26-32
Shimizu E1, Takehisa Y1, Bando H1,2,3*, Fujita M1, Kusaka Y1, Yuu M1
1Eto Hospital, Hakuai Group, Tokushima, Japan
2Medical Research/Tokushima University, Tokushima, Japan
3Japan Low Carbohydrate Diet Promotion Association (JLCDPA), Kyoto, Japan
Corresponding Author: Hiroshi BANDO, MD, PhD
Address: Medical Research/Tokushima University, Nakashowa 1-61, Tokushima 770-0943, Japan; Tel: +81-90-3187-2485, Fax: +81-88-603-1030; Email: pianomed@bronze.ocn.ne.jp
Received date: 20 March 2020; Accepted date: 6 April 2020; Published date: 14 April 2020
Abstract
The case was a 55-year-old female patient with depression for 5 years and type 2 diabetes mellitus (T2DM) for 3 years. She has received anti-depressant and anti-hyperglycemic agents (OHAs). Approximately 1 year ago, her diabetic control became exacerbated without specific triggers. She was started to given Ipragliflozin L-Proline as Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. After that, her glucose variability and depression had been improved. According to the previous reports, SGLT-2 inhibitors seem to have anti-depression efficacy for diabetes. The case has been followed up in detail, and this report is expected to be a useful reference for diabetes care.
Citation: Shimizu E, Takehisa Y, Bando H, Fujita M, Kusaka Y, Yuu M. Effective SGLT2 Inhibitor for Patient with Type 2 Diabetes Mellitus (T2DM) and Depression. Diab Res Open Access. 2020 Apr 14;2(S1):26-32.
Copyright © 2020 Shimizu E, Takehisa Y, Bando H, Fujita M, Kusaka Y, Yuu M. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor; Ipragliflozin L-Proline; Depression; Oral Hypoglycemic Agents (OHA); Low-Carbohydrate Diet (LCD)
Abbreviations: T2DM: Type 2 Diabetes Mellitus; SGLT2: Sodium-Glucose Cotransporter-2; LCD: Low-Carbohydrate Diet; OHA: Oral Hyperglycemic Agents; DPP-4: Dipeptidyl Peptidase-4
